A multi-center, multiple-ascending dose, randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO4909832 following intravenous infusion in AD patients.

Trial Profile

A multi-center, multiple-ascending dose, randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO4909832 following intravenous infusion in AD patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Mar 2016

At a glance

  • Drugs Gantenerumab (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
  • Sponsors Roche
  • Most Recent Events

    • 11 Oct 2011 Results of a substudy in 16 patients published in the Archives of Neurology.
    • 23 Feb 2010 Last checked against Roche record.
    • 18 Nov 2009 Status changed from active, no longer recruiting to completed as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top